Quality of Life in SMA Patients Under Treatment With Nusinersen

Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Neurol
Asıl Yazarlar: Mix, Lucas, Winter, Benedikt, Wurster, Claudia D., Platen, Sophia, Witzel, Simon, Uzelac, Zeljko, Graf, Heiko, Ludolph, Albert C., Lulé, Dorothée
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Neurology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8039289/
https://ncbi.nlm.nih.gov/pubmed/33854472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2021.626787
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller